KALA · KALA BIO, Inc.

On November 9, 2025, the Reporting Person, as "Lender", entered into a Convertible Loan Agreement (the "Agreement") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the "Conversion Price" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash.

Not applicable.

On November 24, 2025, David E. Lazar (the "Reporting Person") and KALA BIO, Inc. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired an aggregate of 900,000 shares of the Company's Series AA Convertible Non-Redeemable Preferred Stock (the "Series AA Preferred Stock") at a price of $2.00 per share, for a total purchase price of $1,800,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing, an aggregate of 2,100,000 shares of the Company's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock", and together with the Series AA Preferred Stock, the "Preferred Stock") at a price of $2.00 per share, for an additional purchase price of $4,200,000.

Each share of Series AA Preferred Stock will be convertible into 55 shares of the Company's common stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock will be convertible into 420 shares of the Company's common stock at any time, subject to certain ownership limitations. No shares of Preferred Stock will be convertible until the Company's stockholders approve a) an increase in the Company's authorized capital to enable the Company to issue all of the shares of common stock that are issuable upon the conversion of the Preferred Stock and b) the conversion of the Preferred Stock into shares of common stock in accordance with the listing rules of The Nasdaq Stock Market, LLC (the "Stockholder Approval").

Following receipt by the Company of the Stockholder Approval, the shares of Series AA Preferred Stock will be convertible at the option of the Reporting Person for no additional consideration.

The Series AA Preferred Stock is perpetual and therefore has no expiration date.

Includes 28,906 unvested RSUs.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 103,540 unvested RSUs.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 35,732 unvested RSUs.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 35,952 unvested RSUs.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 28,906 unvested RSUs.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 28,878 unvested RSUs.

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $1.27 to $1.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $1.27 to $1.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J.Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of KALA BIO, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $1.50 to $1.84, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J.Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of KALA BIO, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $1.50 to $1.84, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

This option was granted on August 29, 2025 and vests over four years beginning on the vesting commencement date of August 29, 2025, with 1/48th of the shares underlying the option vesting at the end of each successive one-month period thereafter until August 29, 2029, subject to the Reporting Person's continued service.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 103,540 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 28,878 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 35,952 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 28,906 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 35,732 unvested RSUs.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Includes 6,355 unvested RSUs.

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Includes 156,492 unvested RSUs.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Includes 7,776 unvested RSUs.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Includes 5,134 unvested RSUs.

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Includes 8,061 unvested RSUs.

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Includes 4,973 unvested RSUs.

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 40,953 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

This amendment is being filed solely to correct the nature of the transaction reported in Column 4 of Table I of the Form 4 filed by the Reporting Person on June 4, 2025. As reported in this amendment, such transaction resulted in a "disposition" of common stock by the Reporting Person and not an "acquisition" as previously reported.

Includes 154,042 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 41,159 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 52,402 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 51,963 unvested RSUs.

This option was granted on March 7, 2025 and vests as to 1/12th of the shares underlying the option at the end of each successive one-month period over a one-year period following February 11, 2025, subject to the Reporting Person's continued employment with the Issuer.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2025, as to 1/3 of the shares underlying the RSUs on January 6, 2026 and as to the final 1/3 of shares underlying the RSUs on January 6, 2027.

Includes 42,966 unvested RSUs.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028.

Includes 49,523 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 194,739 unvested RSUs.

This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028.

Includes 64,324 unvested RSUs.

This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer.

This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 64,324 unvested RSUs.

This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 49,523 unvested RSUs.

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028.

Includes 194,739 unvested RSUs.